PURPOSE: To investigate whether the presence of single nucleotide polymorphisms (SNPs) located within TGFB1 might be predictive for the development of adverse quality-of-life outcomes in prostate cancer patients treated with radiotherapy. METHODS AND MATERIALS: A total of 141 prostate cancer patients treated with radiotherapy were screened for SNPs in TGFB1 using DNA sequencing. Three quality-of-life outcomes were investigated: (1) prospective decline in erectile function, (2) urinary quality of life, and (3) rectal bleeding. Median follow-up was 51.3 months (range, 12-138 months; SD, 24.4 months). RESULTS: Those patients who possessed either the T/T genotype at position -509, the C/C genotype at position 869 (pro/pro, codon 10) or the G/C genotype at position 915 (arg/pro, codon 25) were significantly associated with the development of a decline in erectile function compared with those who did not have these genotypes: 56% (9 of 16) vs. 24% (11 of 45) (p = 0.02). In addition, patients with the -509 T/T genotype had a significantly increased risk of developing late rectal bleeding compared with those who had either the C/T or C/C genotype at this position: 55% (6 of 11) vs. 26% (34 of 130) (p = 0.05). CONCLUSIONS: Possession of certain TGFB1 genotypes is associated with the development of both erectile dysfunction and late rectal bleeding in patients treated with radiotherapy for prostate cancer. Therefore, identification of patients harboring these genotypes may represent a means to predict which men are most likely to suffer from poor quality-of-life outcomes after radiotherapy for prostate cancer.
PURPOSE: To investigate whether the presence of single nucleotide polymorphisms (SNPs) located within TGFB1 might be predictive for the development of adverse quality-of-life outcomes in prostate cancerpatients treated with radiotherapy. METHODS AND MATERIALS: A total of 141 prostate cancerpatients treated with radiotherapy were screened for SNPs in TGFB1 using DNA sequencing. Three quality-of-life outcomes were investigated: (1) prospective decline in erectile function, (2) urinary quality of life, and (3) rectal bleeding. Median follow-up was 51.3 months (range, 12-138 months; SD, 24.4 months). RESULTS: Those patients who possessed either the T/T genotype at position -509, the C/C genotype at position 869 (pro/pro, codon 10) or the G/C genotype at position 915 (arg/pro, codon 25) were significantly associated with the development of a decline in erectile function compared with those who did not have these genotypes: 56% (9 of 16) vs. 24% (11 of 45) (p = 0.02). In addition, patients with the -509 T/T genotype had a significantly increased risk of developing late rectal bleeding compared with those who had either the C/T or C/C genotype at this position: 55% (6 of 11) vs. 26% (34 of 130) (p = 0.05). CONCLUSIONS: Possession of certain TGFB1 genotypes is associated with the development of both erectile dysfunction and late rectal bleeding in patients treated with radiotherapy for prostate cancer. Therefore, identification of patients harboring these genotypes may represent a means to predict which men are most likely to suffer from poor quality-of-life outcomes after radiotherapy for prostate cancer.
Authors: Kimberly E Alexander; Suzanne Chambers; Amanda B Spurdle; Jyotsna Batra; Felicity Lose; Tracy A O'Mara; Robert A Gardiner; Joanne F Aitken; Judith A Clements; Mary-Anne Kedda; Monika Janda Journal: Qual Life Res Date: 2015-02-28 Impact factor: 4.147
Authors: J Joshua Smith; Isaac Wasserman; Sarah A Milgrom; Oliver S Chow; Chin-Tung Chen; Sujata Patil; Karyn A Goodman; Julio Garcia-Aguilar Journal: Int J Radiat Oncol Biol Phys Date: 2016-12-18 Impact factor: 7.038
Authors: Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa Journal: J Natl Cancer Inst Date: 2010-06-28 Impact factor: 13.506
Authors: Sarah L Kerns; Harry Ostrer; Richard Stock; William Li; Julian Moore; Alexander Pearlman; Christopher Campbell; Yongzhao Shao; Nelson Stone; Lynda Kusnetz; Barry S Rosenstein Journal: Int J Radiat Oncol Biol Phys Date: 2010-12-01 Impact factor: 7.038
Authors: Carmen A Perez; Heidi Chen; Yu Shyr; Regina Courtney; Wei Zheng; Qiuyin Cai; Misun Hwang; Jerry Jaboin; Stephen Schleicher; Luigi Moretti; Marcia Wills; Joseph A Smith; Bo Lu Journal: J Urol Date: 2010-03-19 Impact factor: 7.450
Authors: Chris R Kelsey; Isabel L Jackson; Scott Langdon; Kouros Owzar; Jessica Hubbs; Zeljko Vujaskovic; Shiva Das; Lawrence B Marks Journal: Clin Lung Cancer Date: 2013-01-10 Impact factor: 4.785
Authors: Andreas Meyer; Thilo Dörk; Natalia Bogdanova; Maria-Jantje Brinkhaus; Birgitt Wiese; Jörn Hagemann; Jürgen Serth; Michael Bremer; Rolf Baumann; Johann H Karstens; Stefan Machtens Journal: World J Urol Date: 2008-11-28 Impact factor: 4.226